The companion diagnostics market reached USD 5.82 billion in 2025 and is projected to grow to USD 15.25 billion by 2035, compounding at 10.1 percent annually. Precision medicine adoption and the proliferation of targeted cancer therapies are the primary expansion drivers, as pharmaceutical manufacturers systematically embed biomarker testing into clinical development pipelines and regulatory pathways increasingly facilitate joint therapeutic-diagnostic approvals. Oncology dominates clinical demand, with lung cancer representing the largest indication segment due to the breadth of actionable mutations including EGFR, ALK, ROS1, BRAF, KRAS, and PD-L1 across multiple therapeutic classes.
What is driving growth
Precision medicine frameworks and targeted therapy adoption are reshaping treatment paradigms across oncology and specialty care, generating systematic demand for biomarker identification and patient stratification. Pharmaceutical manufacturers have integrated companion diagnostics into development pipelines, with regulatory pathways at the FDA and EMA now expediting simultaneous therapeutic-diagnostic approvals. Expanding industrial capacity and broadening molecular testing applications across oncology, rare diseases, and infectious disease treatment are amplifying end-user demand. Government infrastructure modernization programs and public sector healthcare spending cycles provide consistent demand anchors across North America, Europe, and emerging markets. Product innovation in liquid biopsy, AI-enabled interpretation, and next-generation sequencing is simultaneously improving clinical utility and reducing per-test costs, accelerating adoption across hospital and laboratory networks.
Restraints and challenges
Companion diagnostic development demands substantial capital investment spanning biomarker discovery, assay optimization, clinical validation, and regulatory compliance, with synchronized approval requirements for both therapeutics and diagnostics extending commercialization timelines and inflating total costs. Smaller diagnostic firms frequently lack financial and operational capacity to conduct large-scale validation studies and navigate heterogeneous reimbursement policies that limit coverage in certain regions. Raw material price volatility and logistics disruptions compress margins particularly for regional manufacturers, while evolving environmental and safety standards increase development timelines and approval costs. Regulatory framework divergence across jurisdictions and emerging complexity around AI-enabled diagnostics further elevate compliance burdens and resource requirements.
Assays, kits and reagents account for 67.3 percent of the market by value, reflecting their consumable nature and recurring use across PCR, NGS, IHC, and ISH-based testing workflows. Tissue samples remain the dominant specimen type because approved and reimbursed companion diagnostic workflows continue to emphasize tissue-based analysis for solid tumors, though liquid biopsy innovations are expanding applicability to blood-derived biomarkers and longitudinal monitoring. Technology-wise, PCR holds the largest share due to its speed, lower cost, and established adoption across targeted mutation testing, though next-generation sequencing platforms are gaining share as costs decline and clinical evidence mounts.
Pharmaceutical and biotechnology companies command the largest end-user share, driven by their central role in CDx co-development, patient stratification in clinical trials, regulatory submissions, and commercialization of matched therapies. North America accounts for 44.7 percent of global revenue, reflecting mature healthcare infrastructure, high molecular testing penetration, and robust reimbursement coverage. Key competitors including F.
Companies profiled
- NGS platforms
- IHC/ISH solutions
- NGS
- IHC
- ISH/FISH
- Thermo Fisher Scientific Inc
- Agilent Technologies Inc
- QIAGEN N.V
For complete market sizing, forecasts, and competitive intelligence, read the full Companion Diagnostics Market — covering growth drivers, regional analysis, and leading company profiles through 2033.